News | Antiplatelet and Anticoagulation Therapies | July 25, 2017

Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice

British researchers find general practitioners are equally likely to prescribe anticoagulants to people without atrial fibrillation as those with it

Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice

July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

The study, published in the British Journal of General Practice, was carried out by researchers at the University of Birmingham’s Institute of Applied Health Research.

Best practice guidelines recommend anticoagulant drugs such as warfarin are prescribed to patients with atrial fibrillation (AF), a heart condition that causes an irregular heartbeat.

First author Nicola Adderley, Ph.D., said, “These patients are at high risk of stroke and anticoagulant drugs greatly reduce the stroke risk as they make blood less likely to clot.

“However, because they reduce blood clotting, patients taking anticoagulant drugs are at risk of bleeding complications.

“Therefore, safety advice is to avoid anticoagulants in patients who have certain conditions such as a bleeding peptic ulcer, diabetic eye disease or a previous stroke caused by a bleed.”

The researchers reviewed patient records from 645 general practices over a 12-year period between 2004 and 2015. They found that AF patients with conditions making them a safety risk and those without safety risks were almost equally likely to be prescribed anticoagulants. The situation did not change over time.

Corresponding author Prof. Tom Marshall, Ph.D., said, “Our study shows that safety advice seems not to influence the prescribing of anticoagulants. We found that patients considered a safety risk were just as likely to be prescribed the drugs as those without safety risks, and this occurred in every year between 2004 and 2015.

“Because anticoagulants prevent strokes in people with this type of irregular pulse, GPs are encouraged to prescribe more anticoagulants to those who need them. This has been happening and it is good news. But the sting in the tail is that more people who perhaps shouldn’t be on anticoagulants are also taking them: about 38,000 nationally.

“We need to understand the reasons for this and whether patients might come to any harm,” he said.

For more information: www.bjgp.org


Related Content

News | Antiplatelet and Anticoagulation Therapies

August 28, 2023 — Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not ...

Home August 28, 2023
Home
News | Antiplatelet and Anticoagulation Therapies

March 24, 2023 — According to the U.S. Food and Drug Administration (FDA), Ascend Laboratories LLC is voluntarily ...

Home March 24, 2023
Home
News | Antiplatelet and Anticoagulation Therapies

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

Home November 14, 2022
Home
News | Antiplatelet and Anticoagulation Therapies

November 17, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline ...

Home November 17, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE ...

Home November 09, 2021
Home
News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
Subscribe Now